Trial Profile
A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor antagonist) administered orally in patients with postherpetic neuralgia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Olodanrigan (Primary)
- Indications Postherpetic neuralgia
- Focus Proof of concept; Therapeutic Use
- Sponsors Spinifex Pharmaceuticals
- 30 Sep 2016 Results of sub-group anaysis (subgroup of patients taking or not taking any concomitant medications) presented at the 16th World Congress on Pain
- 08 Feb 2014 Results published in the Lancet.
- 05 Feb 2014 Results have been published in the Lancet according to a Spinifex Pharmaceuticals media release. Results were also reported in the media release.